Pacific Biosciences of California, Inc. (PACB) is a publicly traded Healthcare sector company. As of September 3, 2026, PACB trades at $1.29 with a market cap of $410.30M and a P/E ratio of -2.99. PACB moved -1.89% today. Year to date, PACB is -29.35%; over the trailing twelve months it is +4.84%. Its 52-week range spans $0.85 to $2.73. Analyst consensus is neutral with an average price target of $2.31. Rallies surfaces PACB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for PACB combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $1.29 |
| Market Cap | $410.30M |
| P/E Ratio | -2.99 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.73 |
| 52-Week Low | $0.85 |
| Volume | 4.90M |
| Avg Volume | 0 |
| Revenue (TTM) | $159.27M |
| Net Income | $-131.39M |
| Gross Margin | 36.38% |
4 analysts cover PACB: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.31.